Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases 28 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq:...

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference 1 October 2020 LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) (“Silence” or “the...